Moderna plans to grow revenue by 10% by 2026 by focusing on expanding its vaccine offering from four to six approved products by 2028, including influenza and combined influenza/COVID vaccines.[1] The company will use revenue from Spikevax, mRESVIA and mNEXSPIKE to fund programs in oncology and rare diseases, expecting to break even by 2028.[1] In oncology, he continues with eight clinical trials in the 2nd and 3rd phases for the drug intismeran autogene in several types of tumors in cooperation with Merck.[1] Moderna has reduced expected costs to about $4.2 billion in 2026 and $3.5 to $3.9 billion in 2027 through cost-cutting measures and research prioritization.[1] As part of the restructuring, it is ending four programs, including clinical development against cytomegalovirus and herpes simplex virus.[1] The firm closed a five-year credit line of up to $1.5 billion from Ares Management Credit Funds and is investing $140 million in a new production line in Norwood, Massachusetts.[1] From 2022, it has streamlined production, ditched eight suppliers and built three of its own plants in the UK, Canada and Australia, expecting to improve gross margins by 10% in three years.[1]